Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BicycleTx TSLP compound Bicycle 46
- Development stage
- Unknown
- Lead developer
- Bicycle Therapeutics
- Modality
- Peptides
01
Overview
BicycleTx TSLP compound Bicycle 46: sourced facts only. name: "This resulted in the potent Bicycle 46 with nanomolar affinity to TSLP (KD = 13 nM), low plasma clearance of 6.4 mL/min/kg, and an effective half-life of 46 min after intravenous dosing to rats." [PMID:38284169]; target: "This resulted in the potent Bicycle 46 with nanomolar affinity to TSLP (KD = 13 nM), low plasma clearance of 6.4 mL/min/kg, and an effective half-life of 46 min after intravenous dosing to rats." [PMID:38284169]; developer: "BicycleTx Limited, Portway Building, Granta Park, Cambridge CB21 6GS, U.K." [PMID:38284169]; modality: "Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin." [PMID:38284169]
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on BicycleTx TSLP compound Bicycle 46.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BicycleTx TSLP compound Bicycle 46.